EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC0

A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity

Negar Alami iD, David C Carter, Nisha V Kwatra, Weihan Zhao, Linda Snodgrass, Ariel R Porcalla, Cheri E Klein, Daniel E Cohen, Loretta Gallenberg, Melina Neenan, Robert A Carr, Kennan C Marsh und 1 weitere

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011392 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Negar Alami und 12 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, North Chicago, Illinois, United States of America. Hauptthemen laut MEDLINE: Wolbachia, Onchocerciasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The parasitic filariae responsible for onchocerciasis and lymphatic filariasis are host to an endosymbiotic bacterium, Wolbachia , which is essential to the fertility and development of the parasites. We performed a Phase-I pharmacokinetic, safety and food-effect study on single and multiple ascending doses of flubentylosin (ABBV-4083), a macrolide antibacterial with activity against Wolbachia , intended to sterilize and eliminate the parasites.

Methods

Seventy-eight healthy adults were exposed to flubentylosin; 36 were exposed to single ascending 40, 100, 200, 400 or 1000 mg doses; 12 received 1000 mg in the food-effect part; and 30 received multiple ascending daily doses of 100 mg for 7 days, 200 mg for 7 or 14 days, or 400 mg for 7 or 14 days. Twenty-two subjects received placebo.

Results

Maximum concentrations (C max ) of flubentylosin were reached after 1–2 hours, with a half-life < 4 hours at doses ≤ 400 mg. C max and AUC increased in a more than dose-proportional manner, with similar exposure after multiple dose administration. The most frequently reported adverse events were nausea (8/78, 10%) and headache (6/78, 8%). Two subjects given a single dose of flubentylosin 1000 mg in the food-effect part experienced reversible asymptomatic ALT and AST elevations at Grade 2 or Grade 4, with no elevation in bilirubin, deemed related to study drug. The effect of food on exposure parameters was minimal. No treatment-related serious adverse events were reported.

Discussion

Flubentylosin 400 mg for 14 days was the maximum tolerated dose in this first-in-human, Phase-I study in healthy adults. Based on preclinical pharmacokinetic/pharmacodynamic modeling, flubentylosin 400 mg once daily for 7 or 14 days is expected to be an effective dose. A Phase-II, proof-of-concept study with flubentylosin using these regimens is currently ongoing in patients with onchocerciasis in Africa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WolbachiaOnchocerciasisAdultHumansTylosinDouble-Blind MethodAnti-Bacterial AgentsMacrolidesArea Under CurveDose-Response Relationship, DrugAdministration, Oral

Substanzen

TylosinAnti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • AbbVie, North Chicago, Illinois, United States of America.
  • Pfizer, Chicago, Illinois, United States of America.
  • Retirees of AbbVie, Chicago, Illinois, United States of America.
  • Food and Drug Administration, Silver Spring, Maryland, United States of America.

ORCID-Profile: Negar Alami

Förderung

  • AbbVie

Zitieren

APA

Alami, N., Carter, D. C., Kwatra, N. V., Zhao, W., Snodgrass, L., Porcalla, A. R., Klein, C. E., Cohen, D. E., Gallenberg, L., Neenan, M., Carr, R. A., Marsh, K. C., & Kempf, D. J. (2023). A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011392

Vancouver

Alami N, Carter DC, Kwatra NV, Zhao W, Snodgrass L, Porcalla AR, et al. A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011392

BibTeX
@article{Alami2023,
  author = {Alami, Negar and Carter, David C and Kwatra, Nisha V and Zhao, Weihan and Snodgrass, Linda and Porcalla, Ariel R and Klein, Cheri E and Cohen, Daniel E and Gallenberg, Loretta and Neenan, Melina and Carr, Robert A and Marsh, Kennan C and Kempf, Dale J},
  title = {A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011392}
}
Kostenlos starten →